T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.01B |
| 2 |
Broadcom
AVGO
|
+$1.49B |
| 3 |
GE Vernova
GEV
|
+$1.19B |
| 4 |
International Paper
IP
|
+$1.05B |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$952M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.31B |
| 2 |
Constellation Energy
CEG
|
+$1.94B |
| 3 |
Qualcomm
QCOM
|
+$1.74B |
| 4 |
NVIDIA
NVDA
|
+$1.71B |
| 5 |
Salesforce
CRM
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.98% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Communication Services | 9.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
CG Oncology
CGON
$6.62B
| $21M | ﹤0.01% |
665,145
-326,973
| -33% | -$11.3M |
|
952
Masco
MAS
$14.7B
| $21M | ﹤0.01% |
314,425
-12,661
| -4% | -$893K |
|
953
BridgeBio Pharma
BBIO
$15.9B
| $20.9M | ﹤0.01% |
824,818
+20,862
| +3% | +$570K |
|
954
Elastic
ESTC
$8.94B
| $20.3M | ﹤0.01% |
178,230
-51,112
| -22% | -$5.37M |
|
|
SFBS
955
ServisFirst Bancshares
SFBS
$5B
| $20.2M | ﹤0.01% |
319,760
-6,036
| -2% | -$373K |
|
956
Reddit
RDDT
$30.4B
| $19.9M | ﹤0.01% |
312,148
-438,348
| -58% | -$23.1M |
|
957
MarketAxess Holdings
MKTX
$5.72B
| $19.9M | ﹤0.01% |
99,403
-48,953
| -33% | -$10.1M |
|
958
Laureate Education
LAUR
$5.15B
| $19.9M | ﹤0.01% |
1,332,164
+1,175,726
| +752% | +$17.6M |
|
959
Teleflex
TFX
$5.82B
| $19.7M | ﹤0.01% |
93,708
-1,230,454
| -93% | -$258M |
|
960
Trimble
TRMB
$13.4B
| $19.6M | ﹤0.01% |
351,371
+6,629
| +2% | +$383K |
|
961
Gulfport Energy Corp
GPOR
$3.01B
| $19.6M | ﹤0.01% |
129,679
+111,679
| +620% | +$17.5M |
|
962
Tencent Music
TME
$14.2B
| $19.5M | ﹤0.01% |
1,387,649
-287,624
| -17% | -$3.86M |
|
|
SLNO
963
DELISTED
Soleno Therapeutics
SLNO
| $19.5M | ﹤0.01% |
477,852
+325,232
| +213% | +$13.8M |
|
964
EPAM Systems
EPAM
$5.24B
| $19.4M | ﹤0.01% |
102,937
+1,498
| +1% | +$319K |
|
965
A.O. Smith
AOS
$8.49B
| $19.3M | ﹤0.01% |
235,683
+1,085
| +0.5% | +$91.8K |
|
966
Snap-on
SNA
$20.9B
| $19.2M | ﹤0.01% |
73,561
+1,038
| +1% | +$285K |
|
967
Healthpeak Properties
DOC
$14.3B
| $19.2M | ﹤0.01% |
977,290
+24,858
| +3% | +$475K |
|
|
CPRX
968
DELISTED
Catalyst Pharmaceutical
CPRX
| $19.1M | ﹤0.01% |
1,232,852
+13,434
| +1% | +$209K |
|
969
Huazhu Hotels Group
HTHT
$12.5B
| $18.9M | ﹤0.01% |
568,305
+699
| +0.1% | +$26.4K |
|
970
Brunswick
BC
$5.29B
| $18.9M | ﹤0.01% |
259,050
-49,293
| -16% | -$4.02M |
|
971
Akamai
AKAM
$18B
| $18.8M | ﹤0.01% |
209,017
-91,502
| -30% | -$8.85M |
|
972
Veeco
VECO
$3.28B
| $18.8M | ﹤0.01% |
402,385
+374,122
| +1,324% | +$14.8M |
|
973
Virtus Investment Partners
VRTS
$1.14B
| $18.6M | ﹤0.01% |
82,261
+2,019
| +3% | +$459K |
|
974
A10 Networks
ATEN
$1.96B
| $18.6M | ﹤0.01% |
1,341,408
+98,616
| +8% | +$1.41M |
|
975
PTC Therapeutics
PTCT
$6.01B
| $18.6M | ﹤0.01% |
606,676
-33,191
| -5% | -$1.08M |
|
Similar funds
T. Rowe Price Associates's Q2 2024 Portfolio in Review
As of Q2 2024, T. Rowe Price Associates held 3,089 positions worth $836B, up 2.4% from $816B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
T. Rowe Price Associates's Q2 2024 filing shows 135 new, 1,850 increased, 836 reduced and 113 closed positions. Its largest new stake was Tempus AI: 5,227,120 shares worth $183M. The largest sale was Microsoft, an estimated $2.31B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2024 buy was Tempus AI: 5,227,120 shares worth $183M.
- T. Rowe Price Associates added most to Apple in Q2 2024, an estimated $4.01B increase.
- T. Rowe Price Associates's biggest Q2 2024 reduction was Microsoft, cutting an estimated $2.31B.
- T. Rowe Price Associates fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $570M.
- T. Rowe Price Associates's ten largest holdings make up 36% of its $836B portfolio in Q2 2024.
- T. Rowe Price Associates opened 135 new positions and closed 113 in Q2 2024.
- T. Rowe Price Associates's portfolio value rose 2.4% quarter-over-quarter to $836B.
Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.